Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assayAchieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.
Read more about our hiPSC cardiomyocyte assay.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
We developed a high-throughput, electrophysiological assay of TREK-1 function to identify novel modulators. The assay was optimized to identify both activators and inhibitors, providing comprehensive mechanistic data for high value, limited supply screening libraries, such as the venom fraction library used in this study (Targeted Venom Discovery Array, T-VDA, Venomtech, UK).